Scinovex
article Open AccessTop 1% cited

Identification of novel <i>FLT‐3</i> Asp835 mutations in adult acute myeloid leukaemia

British Journal of Haematology · 2001 · Vol. 113(4) · pp. 983–988
F. M. Abu‐DuhierAnne GoodeveG. A. WilsonRory CareI. R. PeakeJ. T. Reilly

Abstract

Genomic DNA from 97 cases of adult de novo acute myeloid leukaemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations. Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change. In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541 + 57 A-->G, the patient PCR products were digested with EcoRV and NlaIII respectively. Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1). Alterations affecting Asp835 were not found in 80 normal control DNA samples. In contrast, the nucleotide 2541 + 57 A-->G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele. This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homology with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchMyeloid leukaemiaIdentification (biology)MedicineMyeloidChronic myeloid leukaemiaCancer researchImmunologyBiology

MeSH terms

Acute DiseaseAdolescentAdultAgedAged, 80 and overAnimalsAspartic AcidElectrophoresis, Polyacrylamide GelFemaleGene FrequencyHumansLeukemia, MyeloidMaleMiddle AgedPrognosis

Funding

  • Medical Research Council
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.